“Simplifies the Solution to Optimize Colistin Therapy”

CBA eequivalent to 150 mg Colistin base activity 360 mg Colistimethate Sodium (4.5 miu) is a FDA approved advance formulation of Colistimethate sodium with simple 2 vial loading dose follow by 150 mg every 12 hourly. It’s a reliable salvage therapy for high risk, culture documented infections & COS Pts. It belongs to a group of antibiotics that are called polymyxins. CBA150 is effective against most Gram-negative bacilli and provide better concentration at the site of infection. Currently CBA150 is imported from Thailand in full finished form.

Indications:

CBA 150 is indicated for the treatment of acute or chronic infections due to the following sensitive strains of certain gram-negative bacilli: Acinetobacter baumannii, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa including MDR, XDR & ESBL producing gram negative organisms.

Pharmaceutical Form:

CBA 150 is a sterile parenteral antibiotic. Each vial contains: Sterile Lyophilized powder of Colistimethate Sodium eq. to 150 mg Colistin base activity containing theequivalent of 4.5 MIU or 230 mg Colistimethate sodium in single dose vial Pack

Dosage Guidelines:

Adults or Children 12 years or above:-

Initial/Loading Dose: 9 MIU or 300 mg Colistin-Based Activity (CBA) i.e. (2 vials of CBA 150 mg)
Maintenance Dose:- 150 mg (CBA) or 4.5 MIU BID/12 hourly
Without Loading Dose:- 150 mg (CBA) or 4.5 MIU BID/12 hourly

Renal Impairment:- Creatinine Clearance between 10 and 30 ml/min: 150 mg (CBA) or 4.5 MIU over 1 hour per 24 hourly.
Creatinine Clearance <10 ml/min:- 150 mg (CBA) or 4.5 MIU over 1 hour per 48 hourly.

Storage:

CBA 150 should be stored at or below 30 ˚C and protected from light.